Table 5 Interaction between MSCs and hematologic neoplasms by microvesicles transferring
Type of malignancy/cell (source) | Target | Content | Results | References |
|---|---|---|---|---|
MDS-MSCs | CD34+ cells | miR-10a and miR-15a | Modifying CD34+ cell viability, CFU-GM production, MDM2 and P53 genes expression | [99] |
CML cell line LAMA84 | Human vascular endothelial cells | Different biomolecules | Upregulation of ICAM‐1, VCAM‐1 and IL‐8, pro-angiogenic pattern | [104] |
MM | MSCs | Osteoclast activating factors | Osteoclast differentiation, osteoclast bone resorption activity | [105] |
MM | MSCs | miR-21 and miR-146a | MM cell growth, survival and proliferation, CAF transformation, IL-6 secretion of MSCs | [115] |
B-CLL | Leukemia B cells | CCL3/4, EGR1/2/3, and MYC | Escaping from spontaneous or drug-induced apoptosis, migrating in higher rate and modifying genes more suitably | [106] |
MSCs | Microenvironment | IL-6 and IL-8 | Hematopoiesis inhibition by downregulating the CXCL12, angiopoietin 1, and kit ligand | [71] |
MSC cell line HS5 | CML cell line LAMA84 | IL-8 | Survival, proliferation, migration | [71] |
K562 | BM-MSCs | miR-711 | Suppressed adhesion abilities of BM-MSCs | [107] |
MSCs | AML cell line | miR-222-3p | IRF2/INPP4B signaling inhibition | [108] |
MSCs | AML cell line | TGF-β1, miR-155, and miR-375 | AML cell resistance to tyrosine kinase inhibitors | [111] |
AML | MSCs | miR-150 | Disruption of the CXCR4/ CXCL12 axis | [111] |
AML cell lines; HEL 92.1.7, HL-60, MOLM-14, and U937 | MSCs | mRNA of IGF1R, MMP-9, NPM1, CXCR4, FLT3 FLT3-ITD | Leukemia progression | [71] |
MM-MSC | MM | IL-6, CCL2 Fibronectin | ↓ miR-15a content in MM-MSCs, induces tumor growth and promotes myeloma dissemination | |
ATL | MSCs | Tax viral oncoprotein of HTLV-I | ↓ MSC stemness and improved angiogenesis | [71] |
CML | MSCs | IL-8 | IL-8 secretion, CML cell survival | [112] |
CLL | MSCs | Protein and miRNA | Creation of leukemia-surviving subpopulation of MSCs | [117] |